Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by fuzzyjron Nov 15, 2024 11:10am

66 Views

Post# 36314925

OTC short interest -

can someone post the tax art # please.

Waht a s. T show. When will this incompetent sausage step down!!The incompetence is overwhelming.

SHORT INTEREST

DATE	SHORT INTEREST	% CHANGE	AVG. DAILY SHARE VOL	SPLIT	NEW ISSUE
10/31/2024	112,882	-8.91	19,410	No	No
10/15/2024	123,917	-6.06	6,325	No	No
09/30/2024	131,917	-6.17	14,089	No	No
09/13/2024	140,592	-19.53	37,414	No	No
08/30/2024	174,707	-0.17	15,808	No	No
08/15/2024	175,002	4.24	97,182	No	No
07/31/2024	167,882	-2.89	6,588	No	No
07/15/2024	172,882	-2.26	6,002	No	No
06/28/2024	176,882	-1.12	4,650	No	No
06/14/2024	178,882	-0.56	7,090	No	No